



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: November 7, 2019

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. NOVEMBER 7, 2019

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. November 7, 2019 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results for the quarter/half year ended September 30, 2019.

Please find enclosed Unaudited Standalone and Consolidated Financial Results for the quarter/half year ended September 30, 2019 along with the Limited Review Reports of the Auditors.

The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 3:00 pm.

This is for your information and record.

Thanking You.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: a/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE
FINANCIAL RESULTS**


**TO THE BOARD OF DIRECTORS OF
ERIS LIFESCIENCES LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Company"), for the quarter and six months ended September 30, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Attention is drawn to Note 7 of the Statement which states that the statement of cash flows for the corresponding six months ended September 30, 2018, as reported in the accompanying Statement have been approved by the Company's Board of Directors, but have not been subjected to review.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Gaurav J Shah

(Partner)
(Membership No. 35701)
(UDIN:19035701AAAAGD6101)



Place: Ahmedabad
Date: November 07, 2019



EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013

Eris
Eris Lifesciences Ltd.

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019

Particulars	[₹ in Million except per share data]					
	For Quarter Ended			For Half Year Ended		For Year Ended
	September 30, 2019 (unaudited)	June 30, 2019 (unaudited)	September 30, 2018 (unaudited)	September 30, 2019 (unaudited)	September 30, 2018 (unaudited)	March 31, 2019 (Audited)
Revenue from Operations						
Sale of products	2,684.20	2,597.78	2,370.74	5,281.98	4,597.55	8,811.28
Other operating income	44.79	25.48	37.37	70.27	75.51	154.11
Total Revenue from Operations	2,728.99	2,623.26	2,408.11	5,352.25	4,673.06	8,965.39
Other Income	49.03	27.16	62.39	76.19	107.45	324.99
Total Income	2,778.02	2,650.42	2,470.50	5,428.44	4,780.51	9,290.38
Expenses						
Cost of materials consumed	181.98	155.38	133.29	337.36	267.43	581.88
Purchase of stock-in-trade	228.02	216.45	213.11	444.47	334.68	875.61
Changes in inventories of finished goods, work-in-progress and stock-in-trade	41.53	80.77	6.19	122.30	80.51	(133.99)
Employee benefits expense	467.54	447.76	405.84	915.30	840.66	1,667.66
Finance Costs	3.99	8.52	62.40	12.51	133.16	227.93
Depreciation and amortisation expense	103.82	101.86	70.75	205.68	131.61	315.89
Other expenses	737.86	719.25	679.04	1,457.11	1,338.40	2,637.64
Total Expenses	1,764.74	1,729.99	1,570.62	3,494.73	3,126.45	6,172.62
Profit before Tax	1,013.28	920.43	899.88	1,933.71	1,654.06	3,117.76
Tax Expense						
Current Tax	142.13	200.91	198.35	343.04	364.56	688.67
Deferred Tax	(44.18)	(100.06)	(138.31)	(144.24)	(251.38)	(424.72)
Total Tax Expense	97.95	100.85	60.04	198.80	113.18	263.95
Net Profit for the period / year	915.33	819.58	839.84	1,734.91	1,540.88	2,853.81
Other Comprehensive Income	(0.67)	(3.73)	0.99	(4.40)	0.66	(0.99)
Items that will not be reclassified to profit or loss	(1.03)	(5.74)	1.52	(6.77)	1.02	(1.52)
Income tax relating to items that will not be reclassified to profit or loss	0.36	2.01	(0.53)	2.37	(0.36)	0.53
Total Comprehensive Income	914.66	815.85	840.83	1,730.51	1,541.54	2,852.82
Paid Up Equity Share Capital (Face Value of ₹ 1 each)	137.52	137.52	137.52	137.52	137.52	137.52
Other Equity						11,422.55
Earnings Per Share (of ₹ 1 each) (not annualised) :						
Basic	6.66	5.96	6.10	12.62	11.20	20.75
Diluted	6.65	5.95	6.10	12.60	11.19	20.74

See accompanying notes to the unaudited standalone financial results



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India
Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 / 71841000
• Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Notes to the financial results

1. Statement of Unaudited Standalone Assets and Liabilities

(₹ in Million)

Particulars	As at	As at
	September 30, 2019	March 31, 2019
I. ASSETS :		
(1) Non-current assets		
(a) Property, Plant and Equipment	510.09	538.33
(b) Right-of-use asset	112.92	-
(c) Capital work-in-progress	297.94	7.48
(d) Goodwill	166.60	166.60
(e) Other Intangible assets	4,088.83	4,133.54
(f) Intangible assets under development	33.43	19.82
(g) Financial assets		
Investments	2,947.20	2,743.63
Other financial assets	77.61	76.18
(h) Income tax assets (net)	86.88	67.13
(i) Deferred tax assets (net)	1,524.37	1,377.76
(j) Other non-current assets	53.69	75.51
Total Non current assets	9,899.56	9,205.98
(2) Current assets		
(a) Inventories	686.82	747.03
(b) Financial assets		
Investments	2,052.85	3,061.05
Trade receivables	1,311.98	758.98
Cash and cash equivalents	100.13	64.64
Other bank balances	0.07	0.07
Loans	18.13	20.38
Other financial assets	229.87	112.61
(c) Other current assets	680.82	733.04
Total Current assets	5,080.67	5,497.80
TOTAL- ASSETS	14,980.23	14,703.78
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Equity Share capital	137.52	137.52
(b) Other Equity	13,154.29	11,422.55
Total Equity	13,291.81	11,560.07
(2) Non-current Liabilities		
(a) Financial Liabilities		
Lease Liabilities	66.84	-
Other financial liabilities	18.66	18.32
(b) Long-term provisions	205.76	164.73
(c) Other non-current liabilities	30.64	54.21
Total Non-current liabilities	321.90	237.26
(3) Current liabilities		
(a) Financial Liabilities		
Lease Liabilities	83.38	-
Trade payables		
i) Due to Micro and Small Enterprises	-	9.61
ii) Due to other than Micro and Small Enterprises	758.51	739.67
Other financial liabilities	132.56	1,760.39
(b) Short-term provisions	230.09	192.22
(c) Other current liabilities	146.83	190.03
(d) Income tax liabilities (net)	15.15	14.53
Total Current liabilities	1,366.52	2,906.45
Total Liabilities	1,688.42	3,143.71
TOTAL- EQUITY AND LIABILITIES	14,980.23	14,703.78



2. Statement of Cash Flows for the six months ended September 30, 2019		
		(₹ in Million)
Particulars	For Half Year Ended 30th September, 2019 Unaudited	For Half Year Ended 30th September, 2018 Unaudited (Refer Note 7)
Net cash flow from operating activities		
Profit before tax	1,933.71	1,654.06
Operating profit before working capital changes	2,122.03	1,826.11
A) Net cash flow from operating activities	1,345.59	940.59
B) Net cash flow from investing activities	497.41	172.78
C) Net cash (used) in financing activities	(1,807.51)	(1,119.00)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	35.49	(5.63)
Add : Cash and cash equivalents at the beginning of the period	64.64	88.08
Cash and cash equivalents at end of the period	100.13	82.45

- The above statement of financial results ("the Statement") of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 07, 2019. The Statutory Auditors of the Company have carried out Limited Review of the Statement.
- The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- The Company on November 06, 2018 has acquired 6.71% shareholding of Kinedex Healthcare Private Limited for a consideration of ₹ 107.21 million. The Company has acquired remaining 17.81% shareholding on April 06, 2019 for a consideration of ₹ 213.73 million in Kinedex Healthcare Private Limited making it a wholly owned subsidiary.
- Effective from April 01, 2019, the Company has adopted Ind AS 116 "Leases" and applied it to all lease contracts existing on April 01, 2019 using modified retrospective method. Accordingly, comparatives for previous period / year have not been retrospectively adjusted. . The adoption of standard has resulted into creation of right of use lease asset by ₹ 179.80 and lease liability by ₹ 190.89 million as at April 1, 2019. Also, the following effects have been given.

	(₹ in million)	
Changes [Increase/(decrease)]	For Quarter ended September 30, 2019	For Half year ended September 30, 2019
Depreciation and Amortisation	33.44	66.88
Finance costs on lease liability	3.52	7.52
Lease rent cost	(24.10)	(48.19)
Profit after tax	(8.37)	(17.05)

- The standalone statement of cash flow for the half year ended September 30, 2018 as reported in these financial results have been approved by the Board of Directors, but have not been subjected to review by the Statutory Auditors.
- Figures for the previous periods have been regrouped wherever considered necessary.



Place: Ahmedabad
Date: November 07, 2019

For Eris Lifesciences Limited,



Amlt Bakshi
Chairman and Managing Director
DIN : 01250925

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ERIS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended September 30, 2019 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Attention is drawn to Note 8 to the Statement which states that the statement of consolidated cash flows for the corresponding six months ended September 30, 2019, as reported in the accompanying Statement have been approved by the Parent's Board of Directors, but have not been subjected to review.

4. The Statement includes the results of the following entities:
 - i. Eris Lifesciences Limited (Parent)
 - ii. Aprica Healthcare Private Limited (Subsidiary)
 - iii. Kinedex Healthcare Private Limited (Subsidiary)
 - iv. Eris Therapeutics Private Limited (Subsidiary)
 - v. UTH Healthcare Private Limited (Subsidiary)
 - vi. Eris Healthcare Private Limited (Subsidiary)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of five subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs. 968.47 millions as at September 30, 2019 and total revenues of Rs. 148.89 millions and Rs 341.91 for the quarter and six months ended September 30, 2019 respectively, total net profit after tax of Rs 16.88 millions and Rs. 42.89 millions for the quarter and six months ended September 30, 2019 respectively and total comprehensive income Rs 16.78 millions and Rs 42.69 millions for the quarter and six months ended September 30, 2019 respectively and net cash flows of Rs. 12.33 millions for the six months ended September 30, 2019, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in black ink, appearing to read "Gaurav J Shah".

Gaurav J Shah
Partner
(Membership No. 35701)
(UDIN: 19035701AAAAGF6649)

Place: Ahmedabad
Date: November 07, 2019



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013

Eris
Eris Lifesciences Ltd.

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019

Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
	September 30, 2019 (unaudited)	June 30, 2019 (unaudited)	September 30, 2018 (unaudited)	September 30, 2019 (unaudited)	September 30, 2018 (unaudited)	March 31, 2019 (Audited)
[₹ in Million except per share data]						
Revenue from Operations						
Sale of products	2,804.56	2,718.89	2,605.62	5,523.45	5,076.39	9,672.02
Other operating income	43.38	24.11	36.22	67.49	73.06	149.59
Total Revenue from Operations	2,847.94	2,743.00	2,641.84	5,590.94	5,149.45	9,821.61
Other Income	51.70	28.26	61.53	79.96	96.77	316.94
Total Income	2,899.64	2,771.26	2,703.37	5,670.90	5,246.22	10,138.55
Expenses						
Cost of materials consumed	181.98	155.38	133.29	337.36	267.43	581.88
Purchase of stock-in-trade	232.70	178.36	264.94	411.06	428.60	1,089.32
Changes in inventories of finished goods, work-in-progress and stock-in-trade	42.53	125.19	7.42	167.72	98.28	(134.22)
Employee benefits expense	505.11	471.49	468.95	976.60	959.76	1,906.59
Finance Costs	5.14	9.05	62.49	14.19	133.54	228.95
Depreciation and amortisation expense	117.31	115.11	82.80	232.42	155.55	363.54
Other expenses	787.17	767.44	760.37	1,554.61	1,503.00	2,928.91
Total Expenses	1,871.94	1,822.02	1,780.26	3,693.96	3,546.16	6,964.97
Profit before Tax	1,027.70	949.24	923.11	1,976.94	1,700.06	3,173.58
Tax Expense						
Current Tax	146.97	209.20	204.59	356.17	380.07	710.71
Deferred Tax	(46.38)	(100.51)	(136.54)	(146.89)	(250.66)	(448.60)
Total Tax Expense	100.59	108.69	68.05	209.28	129.41	262.11
Net Profit for the period / year	927.11	840.55	855.06	1,767.66	1,570.65	2,911.47
Attributable to :						
- Owners of the Company	927.11	840.45	853.20	1,767.56	1,565.71	2,907.96
- Non controlling interest	-	0.10	1.86	0.10	4.94	3.51
Other Comprehensive Income	(0.77)	(3.83)	1.19	(4.60)	1.21	(1.13)
Items that will not be reclassified to profit or loss	(1.17)	(5.88)	1.73	(7.05)	1.71	(1.71)
Income tax relating to items that will not be reclassified to profit or loss	0.40	2.05	(0.54)	2.45	(0.50)	0.58
Total Comprehensive Income	926.34	836.72	856.25	1,763.06	1,571.86	2,910.34
Attributable to :						
- Owners of the Company	926.34	836.62	854.39	1,762.96	1,566.92	2,906.83
- Non controlling interest	-	0.10	1.86	0.10	4.94	3.51
Paid Up Equity Share Capital (Face Value of ₹ 1 each)	137.52	137.52	137.52	137.52	137.52	137.52
Other Equity						11,367.66
Earnings Per Share (of ₹ 1 each) (not annualised) :						
Basic	6.74	6.11	6.20	12.85	11.38	21.15
Diluted	6.73	6.11	6.20	12.84	11.37	21.13

See accompanying notes to the unaudited consolidated financial results



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India
Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 / 71841000
• Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Notes to the financial result

1. Statement of Unaudited Consolidated Assets and Liabilities

(₹ in Million)

Particulars	As at	As at
	September 30, 2019	March 31, 2019
I. ASSETS :		
(1) Non-current assets		
(a) Property, Plant and Equipment	527.18	553.23
(b) Right-of-use asset	125.92	-
(c) Capital work-in-progress	297.94	7.48
(d) Goodwill	935.87	935.87
(e) Other Intangible assets	6,050.89	6,116.26
(f) Intangible assets under development	33.43	19.82
(g) Financial assets		
Investments	398.96	409.12
Other financial asset	78.34	76.87
(h) Income tax assets (net)	96.24	76.73
(i) Deferred tax assets (net)	1,591.88	1,447.94
(j) Other non-current assets	53.69	75.51
Total Non-current assets	10,190.34	9,718.83
(2) Current assets		
(a) Inventories	720.91	826.53
(b) Financial assets		
Investments	2,112.19	3,149.42
Trade receivables	1,387.85	839.76
Cash and cash equivalents	122.82	75.00
Other bank balances	0.07	0.07
Loans	19.17	21.25
Other financial assets	246.54	129.47
(c) Income tax assets (net)	1.26	1.26
(d) Other current assets	703.74	775.03
Total Current assets	5,314.55	5,817.79
TOTAL- ASSETS	15,504.89	15,536.62
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Share capital	137.52	137.52
(b) Other Equity	13,101.30	11,367.66
Equity attributable to the owners of the Company	13,238.82	11,505.18
Non-controlling Interest	-	183.11
Total Equity	13,238.82	11,688.29
(2) Non-current liabilities		
(a) Financial Liabilities		
Long term Borrowings	1.78	2.93
Lease Liabilities	81.33	-
Other financial liabilities	20.96	23.51
(b) Long-term provisions	231.66	193.86
(c) Other non-current liabilities	30.64	55.71
(d) Deferred tax liabilities (net)	511.55	516.95
Total Non-current liabilities	877.92	792.96
(3) Current liabilities		
(a) Financial Liabilities		
Lease Liabilities	86.16	-
Trade payables		
A) Due to Micro and Small Enterprises	-	9.61
B) Due to other than Micro and Small Enterprises	729.48	831.64
Other financial liabilities	136.11	1,763.84
(b) Short-term provisions	238.12	210.29
(c) Other current liabilities	175.00	221.88
(d) Income tax liabilities (net)	23.28	18.11
Total Current liabilities	1,388.15	3,055.37
Total Liabilities	2,266.07	3,848.33
TOTAL- EQUITY AND LIABILITIES	15,504.89	15,536.62



2. Statement of Cash Flows for the six months ended September 30, 2019

(₹ In million)

Particulars	Six months ended 30th September, 2019 Unaudited	Six months ended 30th September, 2018 Unaudited (Refer Note 8)
Net cash flow from operating activities		
Profit before tax	1,976.94	1,700.06
Operating profit before working capital changes	2,191.47	1,907.84
A) Net cash flow from operating activities	1,395.16	965.71
B) Net cash flow from investing activities	524.11	192.05
C) Net cash (used) in financing activities	(1,811.45)	(1,120.43)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	47.82	37.33
Add : Cash and cash equivalents at the beginning of the period	75.00	106.08
Cash and cash equivalents at end of the period	122.82	143.41

3. The above statement of financial results ("the Statement") of the Group were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 07, 2019. The Statutory Auditors of the Company have carried out Limited Review of the Statement.

4. The Group is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".

5. The Parent Company on November 06, 2018 has acquired 6.71% shareholding of Kinedex Healthcare Private Limited for a consideration of ₹ 107.21 million. The Company has acquired remaining 17.81% shareholding on April 06, 2019 for a consideration of ₹ 213.73 million in Kinedex Healthcare Private Limited making it a wholly owned subsidiary.

6. Effective from April 01, 2019, the Group has adopted Ind AS 116 "Leases" and applied it to all lease contracts existing on April 01, 2019 using modified retrospective method. Accordingly, comparatives for previous period / year have not been retrospectively adjusted. The adoption of standard has resulted into creation of right of use lease asset by ₹ 196.78 and lease liability by ₹ 209.37 million as at April 1, 2019. Also, the following effects have been given.

(₹ in million)

Changes (Increase/(decrease))	For Quarter ended September 30, 2019	For Half year ended September 30, 2019
Depreciation and Amortisation	35.44	70.86
Finance costs on lease liability	3.92	8.34
Lease rent cost	(25.12)	(50.22)
Profit after tax	(9.37)	(19.05)

7. Information of Standalone Financial Result of the Company is as under:

(₹ In Million)

Particulars	Quarter Ended			For Half Year Ended		Year Ended
	September 30, 2019 (unaudited)	June 30, 2019 (unaudited)	September 30, 2018 (Unaudited)	September 30, 2019 (unaudited)	September 30, 2018 (unaudited)	March 31, 2019 (Audited)
Revenue from Operations	2,728.99	2,623.26	2,408.11	5,352.25	4,673.06	8,965.39
Profit Before Tax	1,013.28	920.43	899.88	1,933.71	1,654.06	3,117.76
Net Profit for the period / year	915.33	819.58	839.84	1,734.91	1,540.88	2,853.81

8. The consolidated statement of cash flow for the half year ended September 30, 2018 as reported in these financial results have been approved by the Board of Directors, but have not been subjected to review by the Statutory Auditors.

9. Figures for the previous periods have been regrouped wherever considered necessary.



For Eris Lifesciences Limited,



Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: November 07, 2019